MRPL Board Approves Increased Holding In ONGC Mangalore Petrochemicals JV

PetroChemical News group

首页> 外文期刊>PetroChemical News >MRPL Board Approves Increased Holding In ONGC Mangalore Petrochemicals JV

【24h】

MRPL Board Approves Increased Holding In ONGC Mangalore Petrochemicals JV

机译：MRPL董事会批准增加在ONGC Mangalore石化合资企业中的控股

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Mangalore— Mangalore Refinery and Petrochemicals Ltd. (MRPL) has notified the Bombay Stock Exchange that its board of directors has approved the acquisition of a major stake in ONGC Mangalore Petrochemicals Ltd. (OMPL), a joint venture between Oil and Natural Gas Corp. (ONGC) and its MRPL subsidiary.

机译：芒格洛尔（Mangalore）-芒格洛尔炼油和石化有限公司（MRPL）已通知孟买证券交易所，其董事会已批准收购ONGC芒格洛尔石油化工有限公司（OMPL）的主要股权，该公司是石油与天然气公司之间的合资企业。（ONGC）及其MRPL子公司。

著录项

来源
《PetroChemical News》 |2015年第7期|共1页
作者
PetroChemical News group;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. MRPL Board Approves Increased Holding In ONGC Mangalore Petrochemicals JV [J] . PetroChemical News group PetroChemical News . 2015,第7期

机译：MRPL董事会批准增加在ONGC Mangalore石化合资企业中的控股
2. MRPL increases stake in ONGC Mangalore Petrochemicals [J] . Plastics news Group Plastics news . 2015,第Null期

机译：MRPL增持ONGC芒格洛尔石油化工股份
3. ONGC evaluates merger of ONGC Mangalore Petrochemicals with MRPL [J] . Popular Plastics amp, Packaging Group Popular Plastics & Packaging . 2014,第8期

机译：ONGC评估ONGC Mangalore石化与MRPL的合并
4. Empirical Study of Board and Corporate Governance Practices in Indian Corporate Sector: Analysis of CG Practices of ITC and ONGC [C] . Ms. Aparna Bajpai, Mita Mehta Symbiosis Institute of Management Studies Annual Research Conference . 2014

机译：印度企业部门董事会和公司治理实践的实证研究：ITC和INGC的CG实践分析
5. An examination of the relationship between board characteristics and capital adequacy risk taking at bank holding companies. [D] . Merle, Jill Ann. 2010

机译：检查董事会特征与银行控股公司承担的资本充足率风险之间的关系。
6. Holding CoVID in check through JAK? The MPN-approved compound ruxolitinib as a potential strategy to treat SARS-CoV-2 induced systemic hyperinflammation [O] . F. Heidel, A. Hochhaus -1

机译：通过JAK持有CoVID支票吗？ MPN批准的化合物ruxolitinib作为治疗SARS-CoV-2引起的系统性过度炎症的潜在策略
7. ACC/AHA/ASNC Guidelines for the Clinical Use of Cardiac Radionuclide Imaging—Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASNC Committee to Revise the 1995 Guidelines for the Clinical Use of Cardiac Radionuclide Imaging)44The ACC/AHA Task Force on Practice Guidelines makes every effort to avoid any actual or potential conflicts of interest that might arise as a result of an outside relationship or personal interest of a member of the writing panel. Specifically, all members of the writing panel are asked to provide disclosure statements of all such relationships that might be perceived as real or potential conflicts of interest. These statements are reviewed by the parent task force, reported orally to all members of the writing panel at the first meeting, and updated as changes occur.55This document was approved by the American College of Cardiology Foundation Board of Trustees in July, 2003, the American Heart Association Science Advisory and Coordinating Committee in July, 2003, and the American Society of Nuclear Cardiology Board of Directors in July, 2003.66When citing this document, the American College of Cardiology Foundation, the American Heart Association, and the American Society of Nuclear Cardiology request that the following citation format be used: Klocke FJ, Baird MG, Bateman TM, Berman DS, Carabello BA, Cerqueira MD, DeMaria AN, Kennedy JW, Lorell BH, Messer JV, O’Gara PT, Russell RO Jr, St. John Sutton MG, Udelson JE, Verani MS, Williams KA. ACC/AHA/ASNC guidelines for the clinical use of cardiac radionuclide imaging—executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASNC Committee to Revise the 1995 Guidelines for the Clinical Use of Radionuclide Imaging). J Am Coll Cardiol 2003;42:1318–33.77(J Am Coll Cardiol 2003;42:1318–33)88©2003 by the American College of Cardiology Foundation and the American Heart Association, Inc. [O] . Klocke Francis J, Baird Michael G, Lorell Beverly H, 2003

机译：ACC / AHA / ASNC心脏放射性核素成像临床使用指南-执行摘要美国心脏病学会/美国心脏协会实践指南工作组的报告（ACC / AHA / ASNC委员会，对1995年临床使用指南进行修订ACC / AHA实践指导小组）竭尽全力避免由于写作小组成员的外部关系或个人利益而引起的任何实际或潜在的利益冲突。具体来说，要求写作小组的所有成员提供所有可能被视为实际或潜在利益冲突的关系的披露声明。这些声明由上级工作组审查，在第一次会议上向书面小组的所有成员口头报告，并在发生变化时进行更新。55本文件于2003年7月获得美国心脏病学会基金会董事会的批准。 2003年7月，美国心脏协会科学咨询与协调委员会，2003年7月，美国核心脏病学会理事会。66引用该文件时，美国心脏病学会基金会，美国心脏协会和美国核学会心脏病学要求使用以下引用格式：Klocke FJ，Baird MG，Bateman TM，Berman DS，Carabello BA，Cerqueira MD，DeMaria AN，Kennedy JW，Lorell BH，Messer JV，O'Gara PT，Russell RO Jr，St John Sutton MG，Udelson JE，Verani MS，Williams KA。 ACC / AHA / ASNC心脏放射性核素成像临床使用指南-执行摘要：美国心脏病学会/美国心脏协会实践小组工作指南（ACC / AHA / ASNC委员会，修订1995年临床指南）的报告使用放射性核素成像）。 J Am Coll Cardiol 2003; 42：1318–33.77（J Am Coll Cardiol 2003; 42：1318–33）88©2003美国心脏病学会基金会和美国心脏协会版权所有。

MRPL Board Approves Increased Holding In ONGC Mangalore Petrochemicals JV

摘要

著录项

相似文献

相关主题

期刊订阅